BioSpace News Archive

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced the appointment of West’s Chief Financial Officer Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer.

Danaher Corporation announced that it has joined the Bespoke Gene Therapy Consortium.

Movano Inc., a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, announces it has successfully validated the functionality of its proprietary and patented system-on-a-chip.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2022.

Veracyte, Inc. announced that an updated clinical guideline from the American Urological Association and the American Society for Radiation Oncology includes a new statement that is favorable for genomic testing, including the Decipher Prostate genomic classifier, to help guide care for men with localized prostate cancer.

Extendicare Inc. reported results for the three months ended March 31, 2022.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three months ended March 31, 2022.

Novanta Inc. announced that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird’s 2022 Global Consumer, Technology & Services Conference on Tuesday, June 7, 2022, in New York, NY.

The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31, 2022.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute.